Mesoblast share price rises after strong quarterly result

The Mesoblast Ltd (ASX: MSB) share price is an early mover after a strong first quarter update from the Aussie medical group.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price has already rocketed 4.83% in early trade after the company's first quarter results update this morning.

Why is the Mesoblast share price moving?

Mesoblast reported its operational highlights and financial results for the first quarter ended 30 September 2019.

The Aussie medical group saw 36% growth on the prior corresponding period (pcp) in group revenues to US$15.0 million. Mesoblast's TEMCELL revenues rocketed 85% higher on pcp in Japan in a boost for the company.

Mesoblast reported a 72% reduction in loss after tax compared to Q1 2019. This was driven by a 33% decrease in research and development expenditure as well as the increase in revenues.

The Mesoblast share price closed 0.56% higher at $1.80 per share yesterday but could climb higher in early trade.

What about operational highlights?

Mesoblast saw continued growth in its commercialisation revenues thanks largely to the Japanese market. The company's acute Graft Versus Host Disease (aGVHD) market adoption in Japan was strong and Mesoblast is hoping for the same in the United States.

The Mesoblast share price will be one to watch today following the broadly positive quarterly update on a financial and operational front.

Mesoblast entered into an agreement with Lonza in October 2019 for commercial product manufacture. The Aussie company is looking to facilitate appropriate inventory build ahead of its planned remestemcel-L launch in the United States.

Mesoblast also entered into a strategic partnership with Grunenthal during the quarter. Mesoblast will receive US$150 million in upfront and milestone payments prior to the MPC-06-ID product launch.

The companies are working together to develop and commercialise the product to treat lower back pain due to a degenerative disc disease.

According to Mesoblast, cumulative milestone payments could exceed US$1 billion depending on the outcome of its Phase 3 studies and patient adoption.

The company has an upcoming FDA filing for its remestemcel-L for aGVHD. If approved, Mesoblast expects to launch the product next year.

The Mesoblast share price is up 49.21% higher in 2019 and has a market cap just over $1 billion.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »